OPTIMAS CAPITAL Ltd Takes $4.01 Million Position in IQVIA Holdings Inc. $IQV

OPTIMAS CAPITAL Ltd bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 21,100 shares of the medical research company’s stock, valued at approximately $4,008,000. IQVIA makes up 2.5% of OPTIMAS CAPITAL Ltd’s holdings, making the stock its 14th largest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Breakwater Capital Group raised its holdings in shares of IQVIA by 4.9% in the 3rd quarter. Breakwater Capital Group now owns 2,130 shares of the medical research company’s stock worth $405,000 after purchasing an additional 100 shares during the period. Candriam S.C.A. increased its position in IQVIA by 61.2% during the 3rd quarter. Candriam S.C.A. now owns 272,747 shares of the medical research company’s stock worth $51,806,000 after purchasing an additional 103,567 shares in the last quarter. New York Life Investment Management LLC lifted its position in IQVIA by 3.2% during the third quarter. New York Life Investment Management LLC now owns 23,050 shares of the medical research company’s stock valued at $4,378,000 after buying an additional 717 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in IQVIA by 81.9% during the third quarter. Smartleaf Asset Management LLC now owns 1,350 shares of the medical research company’s stock worth $244,000 after buying an additional 608 shares during the period. Finally, Canada Post Corp Registered Pension Plan increased its position in shares of IQVIA by 40.3% in the third quarter. Canada Post Corp Registered Pension Plan now owns 2,960 shares of the medical research company’s stock worth $535,000 after acquiring an additional 850 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 3.6%

NYSE IQV opened at $187.50 on Monday. The company has a market capitalization of $31.93 billion, a price-to-earnings ratio of 23.85, a price-to-earnings-growth ratio of 1.90 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company’s fifty day moving average price is $228.03 and its two-hundred day moving average price is $209.87.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. UBS Group reduced their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday. Evercore ISI reaffirmed an “outperform” rating on shares of IQVIA in a research report on Thursday. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday. Jefferies Financial Group reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Evercore reaffirmed an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.75.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.